LIPO — LIPELLA PHARMACEUTICALS INC. COMMON STOCK (Healthcare >> Biotechnology)
LIPO FAQ
What is LIPO's ROE?
LIPELLA PHARMACEUTICALS INC. COMMON STOCK reports a Return on Equity (ROE) of -358.28%.
What is LIPO's dividend yield?
LIPELLA PHARMACEUTICALS INC. COMMON STOCK offers a dividend yield of 0.00%.
What is LIPO's Deepscope Quality Score?
Deepscope rates LIPO's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LIPO?
Deepscope's AI Timing Score for LIPO is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LIPO belong to?
LIPELLA PHARMACEUTICALS INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.08
Price
-0.02
(-21.57%)
Day Change
|
|
|---|
LIPO, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 76 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.08 |
| PBV / Sector |
0.25 / 4.63
GREAT
|
| Earning Per Share | -1.15 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2470.507055000000
|
| Average 1W Daily Value |
2432.097980000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:42 |
| Symbol | LIPO |
| Name | LIPELLA PHARMACEUTICALS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.62 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.37 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7800 Susquehanna St., Pittsburgh, PA, United States, 15208
Phone: 412 894 1853
Website: https://lipella.com
Sector: Healthcare >> Biotechnology
Description: Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google